The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy
Open Access
- 8 December 2016
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (12), 2001
- https://doi.org/10.3390/ijms17122001
Abstract
Diabetes mellitus is a chronic metabolic condition that affects carbohydrate, lipid and protein metabolism and may impair numerous organs and functions of the organism. Cardiac dysfunction afflicts many patients who experience the oxidative stress of the heart. Diabetic cardiomyopathy (DCM) is one of the major complications that accounts for more than half of diabetes-related morbidity and mortality cases. Chronic hyperglycemia and hyperlipidemia from diabetes mellitus cause cardiac oxidative stress, endothelial dysfunction, impaired cellular calcium handling, mitochondrial dysfunction, metabolic disturbances, and remodeling of the extracellular matrix, which ultimately lead to DCM. Although many studies have explored the mechanisms leading to DCM, the pathophysiology of DCM has not yet been fully clarified. In fact, as a potential mechanism, the associations between DCM development and mitogen-activated protein kinase (MAPK) activation have been the subjects of tremendous interest. Nonetheless, much remains to be investigated, such as tissue- and cell-specific processes of selection of MAPK activation between pro-apoptotic vs. pro-survival fate, as well as their relation with the pathogenesis of diabetes and associated complications. In general, it turns out that MAPK signaling pathways, such as extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal protein kinase (JNK) and p38 MAP kinase, are demonstrated to be actively involved in myocardial dysfunction, hypertrophy, fibrosis and heart failure. As one of MAPK family members, the activation of ERK1/2 has also been known to be involved in cardiac hypertrophy and dysfunction. However, many recent studies have demonstrated that ERK1/2 signaling activation also plays a crucial role in FGF21 signaling and exerts a protective environment of glucose and lipid metabolism, therefore preventing abnormal healing and cardiac dysfunction. The duration, extent, and subcellular compartment of ERK1/2 activation are vital to differential biological effects of ERK1/2. Moreover, many intracellular events, including mitochondrial signaling and protein kinases, manipulate signaling upstream and downstream of MAPK, to influence myocardial survival or death. In this review, we will summarize the roles of ERK1/2 pathways in DCM development by the evidence from current studies and will present novel opinions on “differential influence of ERK1/2 action in cardiac dysfunction, and protection against myocardial ischemia-reperfusion injury”.Keywords
Funding Information
- National Natural Science Foundation of China (81370318, 81573493)
This publication has 105 references indexed in Scilit:
- Endocrine Protection of Ischemic Myocardium by FGF21 from the Liver and Adipose TissueScientific Reports, 2013
- Interference with ERK Thr188 phosphorylation impairs pathological but not physiological cardiac hypertrophyProceedings of the National Academy of Sciences of the United States of America, 2013
- Diabetic cardiomyopathy: pathophysiology and clinical featuresHeart Failure Reviews, 2012
- Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2AJournal of Molecular and Cellular Cardiology, 2011
- Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking TalePhysiological Reviews, 2010
- Diabetic cardiomyopathy, causes and effectsReviews in Endocrine and Metabolic Disorders, 2010
- Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivoProceedings of the National Academy of Sciences of the United States of America, 2007
- Differential regulation and properties of MAPKsOncogene, 2007
- MAPK signalling: ERK5 versus ERK1/2EMBO Reports, 2006
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004